Pfizer's Potency Play


Pfizer is getting quite a lift from Viagra. On Mar. 23, Pfizer stock rose 4.5% to close at 96 1/4, after the ABC News program 20/20 did a segment on the company's promising new impotence treatment. Viagra, which may win marketing approval from the Food & Drug Administration any day now, is expected to be a blockbuster, with possible annual sales of $3 billion by 2002. More good news on Mar. 24: Pfizer announced that its deal to co-promote G.D. Searle's upcoming arthritis drug was expanded to include all areas of the globe except Japan. But that wasn't enough to keep its stock aloft, and it closed Mar. 25 at 94 1/2.

Before it's here, it's on the Bloomberg Terminal.